drugset / Trial / NCT00006864
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Phase 4
Completed
Case Comprehensive Cancer Center
Chiron Corporation · collabNational Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.
Timeline
- Start
- 2000-07
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |